Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
- The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
- 12/15/2023
|
3 Biotech Stocks That Could Be Multibaggers in the Making
- In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
- 11/30/2023
|
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
- Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
- 11/16/2023
|
Arcellx stock climbs on Gilead investment
- Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gilead Sciences Inc's Kite as part of an expanded collaboration. Gilead will buy 3.24 million shares of Arcellx at a price of $61.68 per share, representing a 30% premium to Tuesday's closing price.
- 11/15/2023
|
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
- Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expanded collaboration. Under terms of the investment, Gilead will buy 3.24 million Arcellx shares for $200 million, which will give Gilead a 13% stake in Arcellx, and extend Arcellx's cash runway into 2027.
- 11/15/2023
|
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
- Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/09/2023
|
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
- Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
- 11/09/2023
|
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
- Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.
- 11/02/2023
|
7 Biotech Stocks to Get In Now Before Investors Catch On
- Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
- 10/23/2023
|
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
- Here is how Arcellx, Inc. (ACLX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
- 10/17/2023
|
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
- Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile cells within the body.
- 10/02/2023
|
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 09/04/2023
|
Arcellx (ACLX) Down on Hold for Lead Program CART-ddBCMA
- Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
- 06/21/2023
|
Arcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient death
- Analysts at Baird say they still like the long-term outlook for biotechnology company Arcellx Inc (NASDAQ:ACLX) after a clinical trial for its investigational new drug CART-ddBCMA for relapsed or refractory multiple myeloma was put on hold by the US Food and Drug Administration (FDA) following a patient's death. The analysts said they expected the negative regulatory update from Arcellx on Monday night to weigh on the stock, which closed down 7.2% at US$33.23 on Tuesday.
- 06/20/2023
|
Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates
- Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of $2.52. This compares to loss of $1.56 per share a year ago.
- 05/08/2023
|
5 Stocks With Recent Price Strength That Still Have Upside
- Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
- 05/03/2023
|
Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy?
- Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/25/2023
|
Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know
- Arcellx, Inc. (ACLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 04/21/2023
|
New Strong Buy Stocks for April 21st
- WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
- 04/21/2023
|
New Strong Buy Stocks for April 17th
- IOT, PNTG, ACLX, ELUXY and AB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
- 04/17/2023
|
Best Momentum Stocks to Buy for April 11th
- ACLX, MT and X made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 11, 2023.
- 04/11/2023
|
New Strong Buy Stocks for April 11th
- AGESY, ACLX, MT, X and GBX have been added to the Zacks Rank #1 (Strong Buy) List on April 11, 2023.
- 04/11/2023
|
Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 04/05/2023
|
Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy?
- Arcellx, Inc. (ACLX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 04/04/2023
|
Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates
- Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/29/2023
|
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
- Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/16/2023
|
Arcellx: The Gilead Deal Derisks And Proves Their Technology
- Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead.
- 01/09/2023
|
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatment
- Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' Kite to co-develop and co-commercialize its late-stage product candidate, CART-dddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
- 12/09/2022
|
Why Is Arcellx (ACLX) Stock Up 25% Today?
- Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it's teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ).
- 12/09/2022
|
Gilead to co-develop Arcellx's multiple myeloma drug
- Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company.
- 12/09/2022
|
These Are the 10 Best-Performing IPOs in 2022 Through October
- The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
- 11/16/2022
|
Arcellx: Promising Up And Coming Player In The CAR-T Space
- Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts.
- 08/24/2022
|
Arcellx: The Best Is Yet To Come
- Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology.
- 08/23/2022
|
Arcellx Announces Participation at the Barclays Global Healthcare Conference
- FOSTER CITY, Calif., March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chief executive officer, Rami Elghandour and chief medical officer, Chris Heery, M.D.
- 03/10/2022
|
U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
- U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
- 02/05/2022
|
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
- CAR-T company Arcellx Inc ACLX priced its IPO at $15 per share, raising $123.8 million at the low end of the Company's proposed range of $15 - $17. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/04/2022
|
Arcellx sets IPO terms, looks to raise up to $140.3 million
- Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share.
- 01/31/2022
|